Phase I: Scopolamine Model of Dementia

Anand R, Wesnes KA (1990). Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Advances in neurology. 51: 261-268. 

 

Barker A, Jones R, Prior J, Wesnes KA (1998). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: A 6-year follow-up. International Journal of Geriatric Psychiatry. 13: 244-247.

 

Barker A, Jones R, Simpson PM, Wesnes KA (1995). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers. International Journal of Geriatric Psychiatry. 10: 1059-1062.

 

Ebert U, Oertel R, Wesnes KA, Kirch W (1998). Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. Human Psychopharmacology. 13: 199-210. 

 

Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W (1998). Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. Journal of Clinical Pharmacology. 38: 720-726.

 

Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ (2005). Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. International Journal of Neuropsychopharmacology. 8: 1-15.

 

Jones RW, Wesnes KA, Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. Annals of New York Academy of Sciences. 640: 241-244. 

 

Lenz RA, Baker JD, Locke C, Rueter LE, Mohler EG, Wesnes KA, Abi-Saab W, Saltarelli MD. (2012). The Scopolamine Model as a Pharmacodynamic Marker in Early Drug Development: A New Paradigm? Psychopharmacology 220: 799-807.

 

Wesnes KA (1994). De l’utilité d’un modèle adéquat dans les essai médicamenteux à propos de la maladie d’Alzheimer. Patient Care. 17: 95-104.

 

Wesnes KA, Anand R, Lorscheid T (1990). Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. ACTA Psychiatrica Scandinavica Supplementum. 360: 71-72. 

 

Wesnes KA, Anand R, Simpson PM, Christmas L (1990). The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology 4: 219-232. 

 

Wesnes KA, Jones RW, Kirby J (1991). The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. British Journal of Clinical Pharmacology. 31: 577-578. 

 

Wesnes KA, Revell A (1984). The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology. 84: 5-11. 

 

Wesnes KA, Simpson PM (1988). Can scopolamine produce a model of the memory deficits seen in ageing and dementia? . Practical Aspects of Memory: Current Research and Issues. M. M. Gruneberg, P. E. Morris and R. N. Sykes. Chichester, Wiley. 2: 236-242.

 

Wesnes KA, Simpson PM, Christmas L, Anand R, McClelland GR (1989). The effects of moclobemide on cognition. Journal of Neural Transmission. 28: 91-102. 

 

Wesnes KA, Simpson PM, Kidd A (1987). The use of a scopolamine model to study the nootropic effects of tenilsetam (Cas-997) in man. Medical Science Research-Biochemistry. 15: 1063-1064. 

 

Wesnes KA, Simpson PM, Kidd AG (1988). An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. Human Psychopharmacology. 3: 27-41.

 

Wesnes KA, Simpson PM, White L, Pinker S, Jertz G, Murphy M, Siegfried K (1991). Cholinesterase inhibition in the scopolamine model of dementia. Annals of the New York Academy of Sciences. 640: 268-271. 

 

Zangara A (2003). Huperzine A: An alkaloid with nootropic and neuroprotective properties. Current Topics in Nutraceutical Research. 1: 193-204. 

 

Zangara A (2003). The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacology, Biochemistry and Behaviour. 75: 675-686. 

Get in touch...

 

 

 

  • Twitter B&W